We are delighted to announce the appointment of three key roles on the EFPIA Board: Lars Fruergaard Jørgensen, President and CEO Novo Nordisk will take over as President; Stefan Oelrich, Member of the Board of Management of Bayer AG and Head of its Pharmaceuticals Division and David Loew, Chief Executive Officer of Ipsen, will become first and second Vice Presidents. Over the coming months, EFPIA and its members remain committed to working with MEPs, Member States and other stakeholders to improve access to medicines, while ensuring Europe’s competitiveness.

The research-based pharmaceutical industry can play a critical role in restoring economic growth in Europe and ensuring future competitiveness in an advancing global economy. In 2022 it invested an estimated €44,500 million in R&D in Europe. It directly employs some 865,000 people and generates about three times more employment indirectly – upstream and downstream – than it does directly. However, the sector faces real challenges. Our latest Pharmaceutical Industry in Figures shows that R&D spending growth in China was more than three times higher than in Europe between 2018 and 2022. Read the full report here.

Primary care has the potential to improve diabetes management and outcomes for PwD, and reduce diabetes-related costs. Access to continuous and regular primary care reduces the number of emergency department visits and hospitalisations, and shortens the length of hospital stays. There is strong evidence that primary care can facilitate early diagnosis, provide person-centred care that addresses comorbidities, and help reduce health inequalities. Read more:

• Investing in primary care can improve diabetes outcomes and reduce costs
• The case for investing in primary care policies in diabetes